Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel

Results for "

ion influx

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Calcium Channel (6) CCR (1) EGFR (1) Endogenous Metabolite (3) Isotope-Labeled Compounds (2) PKC (1) Potassium Channel (8) Sodium Channel (13) TRP Channel (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (11) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (18)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	TRP Channel Endogenous Metabolite	Neurological Disease
Farnesyl pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-B0517A

Mepivacaine hydrochloride	Sodium Channel	Neurological Disease
Mepivacaine hydrochloride binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization .

HY-B0517

Mepivacaine	Sodium Channel	Neurological Disease
Mepivacaine is an amide-type local anesthetic agent. Mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization .

HY-B0517S

Mepivacaine-d3	Sodium Channel	Neurological Disease
Mepivacaine-d₃ is the deuterium labeled Mepivacaine. Mepivacaine is an amide-type local anesthetic agent. Mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization[1][2].

HY-N2549

(±)-Abscisic acid (±)-ABA	Calcium Channel	Metabolic Disease Inflammation/Immunology
(±)-Abscisic acid ((±)-ABA) is an orally active phytohormone. (±)-Abscisic acid induces Ca ²⁺ channel opening to facilitate the influx of calcium ions and modulates stomatal movement. (±)-Abscisic acid shows anti-inflammatory activity and has the potential for the research of inflammatory bowel disease (IBD) .

HY-103442

CGP52411 DAPH	EGFR Amyloid-β	Neurological Disease Cancer
CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC₅₀ of 0.3 μM. CGP52411 blocks the toxic influx of Ca ²⁺ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease .

HY-B0517AR

Mepivacaine (hydrochloride) (Standard)	Sodium Channel	Neurological Disease
Mepivacaine (hydrochloride) (Standard) is the analytical standard of Mepivacaine (hydrochloride). This product is intended for research and analytical applications. Mepivacaine hydrochloride binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization .

HY-B0517R

Mepivacaine (Standard)	Sodium Channel	Neurological Disease
Mepivacaine (Standard) is the analytical standard of Mepivacaine. This product is intended for research and analytical applications. Mepivacaine is an amide-type local anesthetic agent. Mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization .

HY-169333

1,4-Dihydropyridine 1,4-DHP	Calcium Channel	Cardiovascular Disease
1,4-Dihydropyridine is an inhibitor for calcium channel, that blocks the L-type calcium channels, reduces the influx of calcium ions into cardiac and vascular smooth muscle cells, and thus reduces the contractility and heart rate of the heart, dilates blood vessels, and lowers blood pressure .

HY-172161

CCR6 antagonist 2	CCR	Inflammation/Immunology
CCR6 antagonist 2 (Compound 20c) is the antagonist for CCR6 with a K_i of 1.1 nM. CCR6 antagonist 2 inhibits CCL20-induced calcium ion influx (IC₅₀ = 4.9 nM), inhibits the chemotactic migration of CCR6+ T cells (IC₅₀ = 190 nM) .

HY-115767

(±)-1,2-Diolein 1,2-Dioleoyl-rac-glycerol	PKC	Others
(±)-1,2-Diolein (1,2-Dioleoyl-rac-glycerol) is a PKC activator. (±)-1,2-Diolein increases myotubes Ca ²⁺ influx .

HY-17611

Etripamil MSP-2017; (-)-MSP-2017	Calcium Channel	Cardiovascular Disease
Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells .

HY-B0563B

Ropivacaine hydrochloride 5 Publications Verification	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .

HY-B0563

Ropivacaine 5 Publications Verification	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .

HY-B0563A

Ropivacaine hydrochloride monohydrate 5 Publications Verification	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine hydrochloride monohydrate is a potent?sodium channel?blocker and blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain?management in vivo .

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	TRP Channel Endogenous Metabolite	Neurological Disease
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-B0563C

Ropivacaine mesylate 5 Publications Verification	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibressup>[1] . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel)?TREK-1?with an IC₅₀?of 402.7 μM in COS-7 cell's membrane .

HY-B0563S1

Ropivacaine-d7	Isotope-Labeled Compounds Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease
Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].

HY-B0563R

Ropivacaine (Standard)	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine (Standard) is the analytical standard of Ropivacaine. This product is intended for research and analytical applications. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .

HY-B0563BS

Ropivacaine-d7 hydrochloride	Isotope-Labeled Compounds Potassium Channel Sodium Channel	Neurological Disease
Ropivacaine-d₇ hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) . Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .

HY-B0563AR

Ropivacaine (hydrochloride monohydrate) (Standard)	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine (hydrochloride monohydrate) (Standard) is the analytical standard of Ropivacaine (hydrochloride monohydrate). This product is intended for research and analytical applications. Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo .

HY-101390

(+)-Niguldipine hydrochloride (S)-Niguldipine hydrochloride	Calcium Channel	Cardiovascular Disease
(+)-Niguldipine hydrochloride is an antagonist for calcium channel. (+)-Niguldipine hydrochloride produces vasodilation by blocking calcium channels and reducing the transmembrane influx of calcium ions. (+)-Niguldipine hydrochloride inhibits U-46619 (HY-108566)-induced coronary vasoconstriction in guinea pig Langendorff heart with pID₅₀ of 11.37, binds to calcium channel on guinea pig skeletal muscle membrane with K_i of 9.75, and lowers the blood pressure in spontaneously hypertensive rat with pED₃₀ of 7.1. (+)-Niguldipine hydrochloride ameliorates cardiovascular diseases such as hypertension, angina pectoris and arrhythmias .

HY-101390A

(-)-Niguldipine hydrochloride (R)-Niguldipine hydrochloride	Calcium Channel	Cardiovascular Disease
(-)-Niguldipine ((R)-Niguldipine) hydrochloride is a calcium channel antagonist. (-)-Niguldipine hydrochloride exerts a vasodilatory effect by blocking calcium channels and reducing the transmembrane influx of calcium ions. (-)-Niguldipine can inhibit U-46619 (HY-108566)-induced coronary artery contraction in guinea pig Langendorff hearts (pID₅₀ of 9.93), has high affinity for calcium channel binding sites on guinea pig skeletal muscle membranes (K_i of 8.10), and lowers blood pressure in spontaneously hypertensive rats (pED₃₀ of 5.55). (-)-Niguldipine hydrochloride can improve cardiovascular diseases such as hypertension, angina pectoris, and arrhythmias .

HY-127022A

Anisodine hydrobromide	Endogenous Metabolite	Neurological Disease
Anisodine hydrobromide is a neuroprotective compound that interacts with muscarinic receptors (M1-M5) in cerebral ischemic diseases. Anisodine hydrobromide effectively reduces exacerbated M1, M2, M4, and M5 receptor expression in brain tissues under hypoxia/reoxygenation conditions. Anisodine hydrobromide demonstrates concentration-dependent inhibition of calcium ion influx and reactive oxygen species (ROS) levels, elucidating its neuroprotective mechanisms. Anisodine hydrobromide leads to decreased aspartate levels in HM cells during hypoxia, highlighting its effects on neurotransmitter modulation. Anisodine hydrobromide holds promising clinical prospects as a potential therapeutic agent for ischemic brain diseases, warranting further investigation into its mechanisms of action.

HY-111527

PPZ2	Calcium Channel	Neurological Disease
PPZ2 is a diacylglycerol (DAG)-activated TRPC3/TRPC6/TRPC7 channel activator with activity in promoting neuronal development and survival. PPZ2 activates recombinant TRPC3/TRPC6/TRPC7 channels in a dose-dependent manner without affecting other TRPC channels. PPZ2 elicits cation currents and calcium ion (Ca(2+)) influx in cultured central neurons. PPZ2 is able to induce BDNF-like neurite outgrowth and neuroprotection, an effect that disappears after TRPC3/TRPC6/TRPC7 knockdown or inhibition. PPZ2 also increases the activation of the calcium-dependent transcription factor cAMP response element binding protein. The effects of PPZ2 suggest that calcium signaling mediated by activation of DAG-activated TRPC channels plays an important role in its neurotrophic effects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	TRP Channel Endogenous Metabolite
Farnesyl pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-N2549

(±)-Abscisic acid (±)-ABA	Structural Classification Natural Products other families Classification of Application Fields Source classification Metabolic Disease Abscisic acid Plants Phytohormone Disease Research Fields Agricultural Research	Calcium Channel
(±)-Abscisic acid ((±)-ABA) is an orally active phytohormone. (±)-Abscisic acid induces Ca ²⁺ channel opening to facilitate the influx of calcium ions and modulates stomatal movement. (±)-Abscisic acid shows anti-inflammatory activity and has the potential for the research of inflammatory bowel disease (IBD) .

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	TRP Channel Endogenous Metabolite
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

Cat. No.	Product Name	Chemical Structure

HY-B0517S

Mepivacaine-d3
Mepivacaine-d₃ is the deuterium labeled Mepivacaine. Mepivacaine is an amide-type local anesthetic agent. Mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization[1][2].

HY-B0563S1

Ropivacaine-d7
Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].

Ropivacaine-d7

Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].

HY-B0563BS

Ropivacaine-d7 hydrochloride
Ropivacaine-d₇ hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) . Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .

Ropivacaine-d7 hydrochloride

Ropivacaine-d₇ hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) . Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks